Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

EverSlim vs Fierce Health

EverSlim
Graded #68

Higher grade

vs+16.9
Fierce Health
Graded #410

Lower grade

The verdict

EverSlim takes it — 73.5/100 to 56.6/100.

EverSlim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. EverSlim is a US telehealth programme selling doctor-prescribed compounded GLP-1 medication delivered to the door, with compounded semaglutide from $117 a month and compounded tirzepatide from $140 a month.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEverSlim +47
80
33
Dose & formulationFierce Health +13
64
77
Clinical oversightEverSlim +14
76
62
Labs & monitoringEverSlim +11
63
52
FulfillmentEverSlim +22
97
75
Contract termsEverSlim +8
55
47
EverSlim · left barFierce Health · right bar

The numbers

MetricEverSlimFierce Health
WeighScore73.5/10056.6/100
GradeCC
Scorecard rank#68#410
Semaglutide$117/mo (compounded)$297/mo (3-month plan, compounded)
Tirzepatide$140/mo (compounded)$497/mo (3-month plan, compounded)
CoverageAll 50 states30 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
EverSlim

Graded #68 · C

Strengths

  • Transparent flat pricing from 127 dollars a month for compounded semaglutide; medication, provider visit, and shipping included with no insurance.
  • Names its pharmacy partners (EPIQ Scripts, Foothills, Emerald) and DrTelx medical group; LegitScript-approved and NABP-accredited.
  • Available in all 50 states and DC, with asynchronous care in 44 states and live-visit access in the rest.
  • Offers both semaglutide and tirzepatide, plus care-team messaging between visits.

Where it loses points

  • No price tiers are published anywhere: /pricing is a 404, the footer pricing link is a same-page anchor, and the checkout is behind a login, so what a titrated dose costs is unknowable before signing up
  • Cancellation requires at least 72 hours' notice before the next billing date, or the subscription renews for another cycle
  • Asynchronous care covers 44 states; DC, Kansas, Louisiana, Mississippi, New Mexico, Rhode Island and West Virginia require a live video consult
  • Marketing says 'No membership' while the cancellation policy repeatedly calls it a membership and a subscription
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
Fierce Health

Graded #410 · C

Strengths

  • 30-state service list spelled out in the Terms — buyers can verify eligibility before intake
  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer on every product page
  • Four GLP-1 programs (standard and microdose semaglutide and tirzepatide) — a broader ladder than peers
  • Microdose tier at $197/mo is one of the lower entry points we've seen

Where it loses points

  • No named 503A compounding pharmacy partner — only generic 'partner pharmacies' language
  • Operating LLC name not disclosed anywhere on the site
  • Tirzepatide weight-loss program ($497/mo) showing 'sold out or unavailable' across all plans at review time
  • Clinical provider network not named
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard